Dose-dependent effect of antipsychotic drugs on autonomic nervous system activity in schizophrenia

BMC Psychiatry

Yoshio Hirayasu⁵  Masataka Taguri²  Toshio Moritani⁴  Norio Ishii¹  Chie Ishii¹  Mami Fujibayashi³  Taku Furuno⁵  Ikuko Kishida¹  Chiaki Kawanishi⁵  Yohko Iwamoto¹ 

[1] Fujisawa Hospital, Kanagawa Prefecture, Japan;Department of Biostatistics and Epidemiology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan;The Division of Physical and Health Education, Setsunan University, Osaka, Japan;Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan;Department of Psychiatry, Yokohama City University School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

关键词: Schizophrenia;    Heart rate variability;    Autonomic nervous system;    Antipsychotic drug;    Adverse drug effect;   

Others  :  1124233
DOI  :  10.1186/1471-244X-12-199

 received in 2012-05-11, accepted in 2012-11-02,  发布年份 2012

【 摘 要 】

Background

Antipsychotic drugs are considered a trigger factor for autonomic dysregulation, which has been shown to predict potentially fatal arrhythmias in schizophrenia. However, the dose-dependent effect of antipsychotic drugs and other psychotropic drugs on autonomic nervous system (ANS) activity remain unclear.The purpose of this study was to investigate the dose-dependent effect of antipsychotic drugs and other clinical factors on ANS activity in an adequate sample size of patients with schizophrenia.

Methods

A total of 211 Japanese patients with schizophrenia and 44 healthy subjects participated in this study. ANS activity was assessed by means of heart rate variability (HRV) power spectral analysis. Antipsychotic drug treatment and various clinical factors were investigated for each participant. The patient group was categorized into three subgroups according to daily dose of antipsychotic drug, and HRV was compared between groups.

Results

The results showed significantly decreased low-frequency and high-frequency components of HRV in the patient group compared to the control group. The high-dose group showed a significantly lower HRV than the medium-dose group and an even lower HRV than the low-dose group. In addition, a significant association between HRV and antipsychotic drug dose was identified by multiple regression analysis. HRV was not associated with age, sex, body mass index, duration of illness, or daily dose of other psychotropic drugs.

Conclusion

These results suggest that antipsychotic drugs exert a significant dose-dependent effect on the extent of decline in ANS activity, and that optimal antipsychotic medication is required to avoid possible cardiovascular adverse events in patients with schizophrenia.

【 授权许可】

   
2012 Iwamoto et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-217.
• [2]Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J: Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950–2005. Schizophr Res 2008, 98:287-294.
• [3]Mortensen PB, Juel K: Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990, 81:372-377.
• [4]Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, Palmer S, Browne C, Wallace C: Sudden death in psychiatric patients. Br J Psychiatry 1998, 172:331-336.
• [5]Chute D, Grove C, Rajasekhara B, Smialek JE: Schizophrenia and sudden death: a medical examiner case study. Am J Forensic Med Pathol 1999, 20:131-135.
• [6]Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH: Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002, 180:515-522.
• [7]Ray WA, Chung CP, Murray KT, Hall K, Stein CM: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235.
• [8]Martin GJ, Magid NM, Myers G, Barnett PS, Schaad JW, Weiss JS, Lesch M, Singer DH: Heart rate variability and sudden death secondary to coronary artery disease during ambulatory electrocardiographic monitoring. Am J Cardiol 1987, 60:86-89.
• [9]Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J: Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993, 88:180-185.
• [10]Bikkina M, Alpert MA, Mukerji R, Mulekar M, Cheng BY, Mukerji V: Diminished short-term heart rate variability predicts inducible ventricular tachycardia. Chest 1998, 113:312-316.
• [11]La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ, ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators: Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998, 351:478-484.
• [12]Kannankeril PJ, Goldberger JJ: Parasympathetic effects on cardiac electrophysiology during exercise and recovery. Am J Physiol Heart Circ Physiol 2002, 282:H2091-H2098.
• [13]Bar KJ, Letzsch A, Jochum T, Wagner G, Greiner W, Sauer H: Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res 2005, 39:519-527.
• [14]Bar KJ, Koschke M, Boettger MK, Berger S, Kabisch A, Sauer H, Voss A, Yeragani VK: Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophr Res 2007, 95:115-123.
• [15]Bar KJ, Wernich K, Boettger S, Cordes J, Boettger MK, Loffler S, Kornischka J, Agelink MW: Relationship between cardiovagal modulation and psychotic state in patients with paranoid schizophrenia. Psychiatry Res 2008, 157:255-257.
• [16]Kim JH, Yi SH, Yoo CS, Yang SA, Yoon SC, Lee KY, Ahn YM, Kang UG, Kim YS: Heart rate dynamics and their relationship to psychotic symptom severity in clozapine-treated schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:371-378.
• [17]Okada T, Toichi M, Sakihama M: Influences of an anticholinergic antiparkinsonian drug, parkinsonism, and psychotic symptoms on cardiac autonomic function in schizophrenia. J Clin Psychopharmacol 2003, 23:441-447.
• [18]Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E: Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001, 21:8-13.
• [19]Cohen H, Loewenthal U, Matar M, Kotler M: Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 2001, 179:167-171.
• [20]Association AP: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA; 1994.
• [21]Inagaki A, Inada T: Dose equivalence of psychotropic drugs: 2006-version. J Clin Psychopharmacol 2006, 9:1443-1447.
• [22]Fujibayashi M, Matsumoto T, Kishida I, Kimura T, Ishii C, Ishii N, Moritani T: Autonomic nervous system activity and psychiatric severity in schizophrenia. Psychiatry Clin Neurosci 2009, 63:538-545.
• [23]Kimura T, Matsumoto T, Akiyoshi M, Owa Y, Miyasaka N, Aso T, Moritani T: Body fat and blood lipids in postmenopausal women are related to resting autonomic nervous system activity. Eur J Appl Physiol 2006, 97:542-547.
• [24]Moritani T, Kimura T, Hamada T, Nagai N: Electrophysiology and kinesiology for health and disease. J Electromyogr Kinesiol 2005, 15:240-255.
• [25]Matsumoto T, Ushiroyama T, Morimura M, Moritani T, Hayashi T, Suzuki T, Tatsumi N: Autonomic nervous system activity in the late luteal phase of eumenorrheic women with premenstrual symptomatology. J Psychosom Obstet Gynaecol 2006, 27:131-139.
• [26]Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ: Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981, 213:220-222.
• [27]Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, Kilborn KM, Barger AC, Shannon DC, Cohen RJ, et al.: Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol 1985, 248:H151-H153.
• [28]Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G, Malfatto G, Dell'Orto S, Piccaluga E, et al.: Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986, 59:178-193.
• [29]Matsumoto T, Miyawaki T, Ue H, Kanda T, Zenji C, Moritani T: Autonomic responsiveness to acute cold exposure in obese and non-obese young women. Int J Obes Relat Metab Disord 1999, 23:793-800.
• [30]Rompelman O, Coenen AJ, Kitney RI: Measurement of heart-rate variability: Part 1-Comparative study of heart-rate variability analysis methods. Med Biol Eng Comput 1977, 15:233-239.
• [31]Matsumoto T, Ushiroyama T, Kimura T, Hayashi T, Moritani T: Altered autonomic nervous system activity as a potential etiological factor of premenstrual syndrome and premenstrual dysphoric disorder. Biopsychosoc Med 2007, 1:24. BioMed Central Full Text
• [32]Rechlin T, Claus D, Weis M: Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994, 35:888-892.
• [33]Mujica-Parodi LR, Yeragani V, Malaspina D: Nonlinear complexity and spectral analyses of heart rate variability in medicated and unmedicated patients with schizophrenia. Neuropsychobiology 2005, 51:10-15.
• [34]Malaspina D, Dalack G, Leitman D, Corcoran C, Amador XF, Yale S, Glassman A, Gorman JM: Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr 2002, 7:53-57.
• [35]Chang JS, Yoo CS, Yi SH, Hong KH, Lee YS, Oh HS, Jung DC, Kim YS, Ahn YM: Changes in heart rate dynamics of patients with schizophrenia treated with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:924-929.
• [36]Toichi M, Kubota Y, Murai T, Kamio Y, Sakihama M, Toriuchi T, Inakuma T, Sengoku A, Miyoshi K: The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol 1999, 31:147-154.
• [37]Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, Skerrett D, Phillips ML, David AS, Peduto A, Gordon E: Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry 2004, 161:480-489.
• [38]Wang YC, Yang CC, Bai YM, Kuo TB: Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. Neuropsychobiology 2008, 57:200-205.